February 1, 2021
Newsroom
Displaying 121–130 of 136
January 27, 2021
Seer Announces Pricing of Upsized Public Offering of Common Stock
January 25, 2021
Seer Announces Proposed Public Offering of Common Stock
January 11, 2021
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
January 11, 2021
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
January 4, 2021
Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 8, 2020
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 4, 2020
Seer Announces Pricing of Initial Public Offering
September 15, 2020
Seer Appoints Catherine Friedman to its Board of Directors
September 15, 2020
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
No results found.
Starting your proteomics research is effortless
Connect with an expert to discuss which path to the full proteome is right for you.
-
Bring the Proteograph Product Suite in-house
-
Run a project with
Seer Technology
Access Center -
Conduct a project with
a Seer service provider
or Center of Excellence